Completed acquisition of Movantik ® from AstraZeneca on April 1, 2020 , and initiated U.S. promotion with net revenues of $7.3 million in April -- Launched commercial sales of Talicia ® in the U.S. in March 2020 ; Talicia ® added to Express Scripts and Prime Therapeutics formularies as an ...
TEL-AVIV, Israel and RALEIGH, N.C. , May 20, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its first quarter 2020 financial results on Wednesday, May 27, 2020 . ...
TEL-AVIV, Israel and RALEIGH, N.C. , May 11, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Dror Ben-Asher , RedHill’s Chief Executive Officer, will present a corporate overview at the UBS ...
The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S. -- All six analyzed moderate-to-severe COVID-19 patients treated with opaganib under compassionate use in Israel were weaned from oxygen and discharged ...
Talicia ® is approved by the U.S. FDA and promoted by RedHill’s U.S. sales force -- Abstract discussing Talicia pharmacokinetics and exposure-response presented as ePoster at Digestive Disease Week ® (DDW) 2020 TEL-AVIV, Israel and RALEIGH, N.C. , May 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma ...
Talicia ® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care therapies --- H. pylori bacterial infection is a Group 1 carcinogen and the strongest risk factor ...
Preliminary data in moderate-to-severe COVID-19 patients treated with opaganib show measurable clinical improvement in all six patients analyzed, including decreased requirement for supplemental oxygenation, higher lymphocyte counts and decreased CRP -- Five of the six patients have been weaned ...
RedHill is pursuing both RHB-107 and opaganib as potential treatments for COVID-19 TEL-AVIV, Israel and RALEIGH, N.C. , April 20, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered ...
Proposed study intended to evaluate the safety and efficacy of opaganib in up to 60 patients hospitalized with positive SARS-CoV-2 infection and pneumonia in the U.S. -- Opaganib’s unique mechanism of action has both anti-viral and anti-inflammatory activities, targeting a critical host factor, ...
All five patients have shown an improved CRP, with four of the five patients also demonstrating measurable clinical improvement, including required supplemental oxygenation and higher lymphocyte counts -- Opaganib was administered to all five patients in addition to standard-of-care, including ...
Menu